Zevra Therapeutics (ZVRA) Scheduled to Post Quarterly Earnings on Monday

Posted by on Aug 12th, 2023

Zevra Therapeutics (NASDAQ:ZVRA – Get Free Report) will be issuing its quarterly earnings data before the market opens on Monday, August 14th. Analysts expect the company to announce earnings of ($0.39) per share for the quarter. Parties that wish to listen to the company’s conference call can do so using this link.

Zevra Therapeutics (NASDAQ:ZVRA – Get Free Report) last issued its quarterly earnings results on Monday, May 15th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.08). Zevra Therapeutics had a negative net margin of 548.93% and a negative return on equity of 38.58%. The business had revenue of $2.88 million during the quarter, compared to analyst estimates of $2.77 million. On average, analysts expect Zevra Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Zevra Therapeutics Stock Performance

Shares of ZVRA opened at $5.20 on Friday. Zevra Therapeutics has a 52-week low of $4.05 and a 52-week high of $6.92. The company has a debt-to-equity ratio of 0.18, a quick ratio of 6.68 and a current ratio of 6.68. The firm has a 50 day simple moving average of $5.15. The firm has a market capitalization of $179.61 million, a price-to-earnings ratio of -3.49 and a beta of 2.22.

Insider Buying and Selling at Zevra Therapeutics

In other news, Director John B. Bode acquired 10,000 shares of the firm’s stock in a transaction dated Thursday, May 18th. The stock was purchased at an average price of $5.04 per share, for a total transaction of $50,400.00. Following the completion of the acquisition, the director now directly owns 10,000 shares in the company, valued at approximately $50,400. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Over the last three months, insiders have acquired 14,740 shares of company stock valued at $74,857. 1.10% of the stock is currently owned by company insiders.

About Zevra Therapeutics

(Get Free Report)

Zevra Therapeutics, Inc, a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications.

Read More

Earnings History for Zevra Therapeutics (NASDAQ:ZVRA)

Receive News & Ratings for Zevra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zevra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.